PAT-505

• Description :

  PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/PAT-505.html

• Concentration :

  10mM

• Purity :

  99.47

• Solubility :

  DMSO : 48.33 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C1=CC=CC(SC2=C(C3CC3)N(C4=CN(CC)N=C4)C5=C2C=CC(Cl)=C5F)=C1F

• Molecular Formula :

  C23H18ClF2N3O2S

• Molecular Weight :

  473.92

• References & Citations :

  [1]Bain G, et al. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis. J Pharmacol Exp Ther. 2017 Jan;360 (1) :1-13. Epub 2016 Oct 17.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Autotaxin

• CAS Number :

  [1782070-22-7]